Introduction of alvimopan into an enhanced recovery protocol for colectomy offers benefit in open but not laparoscopic colectomy

Jeffrey F. Barletta, Theodor Asgeirsson, Khaled I. El-Badawi, Anthony J. Senagore

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Introduction: Alvimopan coupled with an enhanced recovery protocol (ERP) has been shown to reduce length of stay (LOS) after open colectomy, but its role after laparoscopy remains unknown. This study evaluated alvimopan with an established ERP for laparoscopic (LAP), hand-assisted laparoscopic (HAL), and open colectomy. Materials and Methods: Consecutive patients who underwent elective colectomy by any technique were retrospectively identified. Patients were excluded if they developed a major intra-abdominal complication, medical complication, or had a complex preoperative evaluation. Patients were stratified into 4 groups based on the surgical approach (open/HAL vs. LAP) and the use of alvimopan. All patients were managed by using an ERP. The incidence of postoperative ileus (POI) and LOS were compared between alvimopan and control groups for each surgical approach. Results: There were 282 patients. Demographics were similar across the 4 groups. The mean number of alvimopan doses administered was 6.7±2.6. For patients in the open/HAL group (n=149), the incidence of primary ileus was 9.5% (7/74) and 16% (12/75) for alvimopan and control patients, respectively (P=.231). A significant decrease in LOS was noted with alvimopan (5.6±2.5 vs. 6.8±3.3 days, P=.009). For patients after LAP (n=133), there was no significance difference in POI with or without alvimopan (3.9% [3/76] vs. 3.5% [2/57], P=1.00). There was no difference in LOS (3.9±1 vs. 3.7±1.4 days, P=.305). Conclusion: The addition of alvimopan to an established ERP will lead to improvement in clinical outcomes in patients after open/HAL colectomy. The benefit of alvimopan after LAP remains negligible.

Original languageEnglish (US)
Pages (from-to)887-891
Number of pages5
JournalJournal of Laparoendoscopic and Advanced Surgical Techniques
Volume21
Issue number10
DOIs
StatePublished - Dec 1 2011
Externally publishedYes

Fingerprint

alvimopan
Colectomy
Ileus
Length of Stay
Hand

ASJC Scopus subject areas

  • Surgery

Cite this

Introduction of alvimopan into an enhanced recovery protocol for colectomy offers benefit in open but not laparoscopic colectomy. / Barletta, Jeffrey F.; Asgeirsson, Theodor; El-Badawi, Khaled I.; Senagore, Anthony J.

In: Journal of Laparoendoscopic and Advanced Surgical Techniques, Vol. 21, No. 10, 01.12.2011, p. 887-891.

Research output: Contribution to journalArticle

Barletta, Jeffrey F. ; Asgeirsson, Theodor ; El-Badawi, Khaled I. ; Senagore, Anthony J. / Introduction of alvimopan into an enhanced recovery protocol for colectomy offers benefit in open but not laparoscopic colectomy. In: Journal of Laparoendoscopic and Advanced Surgical Techniques. 2011 ; Vol. 21, No. 10. pp. 887-891.
@article{c56c9abfed954dd39603aba8a5d26310,
title = "Introduction of alvimopan into an enhanced recovery protocol for colectomy offers benefit in open but not laparoscopic colectomy",
abstract = "Introduction: Alvimopan coupled with an enhanced recovery protocol (ERP) has been shown to reduce length of stay (LOS) after open colectomy, but its role after laparoscopy remains unknown. This study evaluated alvimopan with an established ERP for laparoscopic (LAP), hand-assisted laparoscopic (HAL), and open colectomy. Materials and Methods: Consecutive patients who underwent elective colectomy by any technique were retrospectively identified. Patients were excluded if they developed a major intra-abdominal complication, medical complication, or had a complex preoperative evaluation. Patients were stratified into 4 groups based on the surgical approach (open/HAL vs. LAP) and the use of alvimopan. All patients were managed by using an ERP. The incidence of postoperative ileus (POI) and LOS were compared between alvimopan and control groups for each surgical approach. Results: There were 282 patients. Demographics were similar across the 4 groups. The mean number of alvimopan doses administered was 6.7±2.6. For patients in the open/HAL group (n=149), the incidence of primary ileus was 9.5{\%} (7/74) and 16{\%} (12/75) for alvimopan and control patients, respectively (P=.231). A significant decrease in LOS was noted with alvimopan (5.6±2.5 vs. 6.8±3.3 days, P=.009). For patients after LAP (n=133), there was no significance difference in POI with or without alvimopan (3.9{\%} [3/76] vs. 3.5{\%} [2/57], P=1.00). There was no difference in LOS (3.9±1 vs. 3.7±1.4 days, P=.305). Conclusion: The addition of alvimopan to an established ERP will lead to improvement in clinical outcomes in patients after open/HAL colectomy. The benefit of alvimopan after LAP remains negligible.",
author = "Barletta, {Jeffrey F.} and Theodor Asgeirsson and El-Badawi, {Khaled I.} and Senagore, {Anthony J.}",
year = "2011",
month = "12",
day = "1",
doi = "10.1089/lap.2011.0209",
language = "English (US)",
volume = "21",
pages = "887--891",
journal = "Journal of Laparoendoscopic and Advanced Surgical Techniques",
issn = "1092-6429",
publisher = "Mary Ann Liebert Inc.",
number = "10",

}

TY - JOUR

T1 - Introduction of alvimopan into an enhanced recovery protocol for colectomy offers benefit in open but not laparoscopic colectomy

AU - Barletta, Jeffrey F.

AU - Asgeirsson, Theodor

AU - El-Badawi, Khaled I.

AU - Senagore, Anthony J.

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Introduction: Alvimopan coupled with an enhanced recovery protocol (ERP) has been shown to reduce length of stay (LOS) after open colectomy, but its role after laparoscopy remains unknown. This study evaluated alvimopan with an established ERP for laparoscopic (LAP), hand-assisted laparoscopic (HAL), and open colectomy. Materials and Methods: Consecutive patients who underwent elective colectomy by any technique were retrospectively identified. Patients were excluded if they developed a major intra-abdominal complication, medical complication, or had a complex preoperative evaluation. Patients were stratified into 4 groups based on the surgical approach (open/HAL vs. LAP) and the use of alvimopan. All patients were managed by using an ERP. The incidence of postoperative ileus (POI) and LOS were compared between alvimopan and control groups for each surgical approach. Results: There were 282 patients. Demographics were similar across the 4 groups. The mean number of alvimopan doses administered was 6.7±2.6. For patients in the open/HAL group (n=149), the incidence of primary ileus was 9.5% (7/74) and 16% (12/75) for alvimopan and control patients, respectively (P=.231). A significant decrease in LOS was noted with alvimopan (5.6±2.5 vs. 6.8±3.3 days, P=.009). For patients after LAP (n=133), there was no significance difference in POI with or without alvimopan (3.9% [3/76] vs. 3.5% [2/57], P=1.00). There was no difference in LOS (3.9±1 vs. 3.7±1.4 days, P=.305). Conclusion: The addition of alvimopan to an established ERP will lead to improvement in clinical outcomes in patients after open/HAL colectomy. The benefit of alvimopan after LAP remains negligible.

AB - Introduction: Alvimopan coupled with an enhanced recovery protocol (ERP) has been shown to reduce length of stay (LOS) after open colectomy, but its role after laparoscopy remains unknown. This study evaluated alvimopan with an established ERP for laparoscopic (LAP), hand-assisted laparoscopic (HAL), and open colectomy. Materials and Methods: Consecutive patients who underwent elective colectomy by any technique were retrospectively identified. Patients were excluded if they developed a major intra-abdominal complication, medical complication, or had a complex preoperative evaluation. Patients were stratified into 4 groups based on the surgical approach (open/HAL vs. LAP) and the use of alvimopan. All patients were managed by using an ERP. The incidence of postoperative ileus (POI) and LOS were compared between alvimopan and control groups for each surgical approach. Results: There were 282 patients. Demographics were similar across the 4 groups. The mean number of alvimopan doses administered was 6.7±2.6. For patients in the open/HAL group (n=149), the incidence of primary ileus was 9.5% (7/74) and 16% (12/75) for alvimopan and control patients, respectively (P=.231). A significant decrease in LOS was noted with alvimopan (5.6±2.5 vs. 6.8±3.3 days, P=.009). For patients after LAP (n=133), there was no significance difference in POI with or without alvimopan (3.9% [3/76] vs. 3.5% [2/57], P=1.00). There was no difference in LOS (3.9±1 vs. 3.7±1.4 days, P=.305). Conclusion: The addition of alvimopan to an established ERP will lead to improvement in clinical outcomes in patients after open/HAL colectomy. The benefit of alvimopan after LAP remains negligible.

UR - http://www.scopus.com/inward/record.url?scp=82455164449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82455164449&partnerID=8YFLogxK

U2 - 10.1089/lap.2011.0209

DO - 10.1089/lap.2011.0209

M3 - Article

VL - 21

SP - 887

EP - 891

JO - Journal of Laparoendoscopic and Advanced Surgical Techniques

JF - Journal of Laparoendoscopic and Advanced Surgical Techniques

SN - 1092-6429

IS - 10

ER -